| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/20/2002 | EP0859632B1 Influenza vaccine compositions |
| 03/20/2002 | EP0800829B1 Antitumor agent potentiator comprising il-6 antagonist |
| 03/20/2002 | EP0672421B1 Endothelin activity inhibitor |
| 03/20/2002 | EP0670726B1 Treatment of hiv infection with humic acid |
| 03/20/2002 | EP0628077B1 Humanised antibodies directed against a33 antigen |
| 03/20/2002 | EP0625043B1 Recombinant multivalent m protein vaccine |
| 03/20/2002 | EP0591385B1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 03/20/2002 | EP0418316B1 Platelet-specific chimeric immunoglobulin |
| 03/20/2002 | CN1341150A 疟疾疫苗 Malaria Vaccine |
| 03/20/2002 | CN1341124A Anti-CD3 immunotoxins and therapeutic use thereof |
| 03/20/2002 | CN1341029A Use of an OmpA enterobacteriumprotein associated with the ELAGIGILTV peptide for treating melanomas |
| 03/20/2002 | CN1341027A Inhibitors for use in hemostasis and immune function |
| 03/20/2002 | CN1340361A Process for preparing xenomal or autogenous tumor vaccine of liposome |
| 03/20/2002 | CN1340360A Immunoactive yolk-albumen composition |
| 03/20/2002 | CN1340359A Two-element active antibody preparation and its preparing process |
| 03/20/2002 | CN1081069C Curative veccinum for hepatitis B and preparing method therefor |
| 03/19/2002 | USRE37596 Hybridoma cell line which produces the monoclonal antibody bw sclc-1 having the deposit number ecacc no. 90022110. |
| 03/19/2002 | US6359127 Oligonucleotide for use in treatment of cancer and nervous system disorders |
| 03/19/2002 | US6359118 Carbohydrate crosslinked glycoprotein crystals |
| 03/19/2002 | US6359054 For gene therapy |
| 03/19/2002 | US6358933 Formulation of nucleic acid and acemannan |
| 03/19/2002 | US6358923 Preventing and diagnosing blood, genetic, and nervous system disorders associated with decreased genetic expression |
| 03/19/2002 | US6358920 Nonapeptide anticarcinogenic and antimetastasis agents |
| 03/19/2002 | US6358744 Stabilized human papillomavirus formulations |
| 03/19/2002 | US6358736 Amplifying preferential polypeptide in tumor cell; obtain cells, incubate with modulator, monitor calcium concentration in cells |
| 03/19/2002 | US6358734 Compounds for treatment of infectious and immune system disorders and methods for their use |
| 03/19/2002 | US6358732 Nucleotide sequences preferential polypeptides for use in the treatment of defects in central nervous system |
| 03/19/2002 | US6358727 Nucleotide sequences coding binding protein for use in treatment and prevention of infections |
| 03/19/2002 | US6358710 Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 |
| 03/19/2002 | US6358709 End selection in directed evolution |
| 03/19/2002 | US6358707 Polynucleotide sequences coding polypeptide associated with cellular secretion; for use in treatment of diabetes, stroke, atherosclerosis, restenosis, thrombosis, autoimmune disease, psoriasis, arthritis, crohn's, and inflammatory defects |
| 03/19/2002 | US6358704 M protein |
| 03/19/2002 | US6358695 Determining compounds that activate or inhibit a g-protein receptor by exposing cells expressing the polypeptide on the surface with a test compound to allow binding and detect a signal in response to binding of agent to the polypeptide |
| 03/19/2002 | US6358694 Culturing prostaglandin receptor expressing cells in the presence of a test compound; measure the modulating affects of the compound that interacts with the recombinant receptor and compare the affects with a control host cell |
| 03/19/2002 | US6358542 Antioxidant compositions extracted from olives and olive by-products |
| 03/19/2002 | US6358524 Target cell-specific non-viral vectors for inserting genes into cells, pharmaceutical compositions comprising such vectors and their use |
| 03/19/2002 | US6358516 To deliver combination of surfactants, humectants, emollients, antimicrobial agents, and other beneficial ingredients in a no-rinse, self-drying formulation that promotes effective absorption into the surface layers of the skin |
| 03/19/2002 | US6358512 Feline infectious peritonitis vaccine |
| 03/19/2002 | US6358510 ICAM-1 derivatives with altered ability to bind LFA-1 |
| 03/19/2002 | US6358509 Administering to animal a polypeptide wherein animal produces antibodies against polypeptide, antibodies being able to specifically bind to human il-4 and are able to inhibit binding of human il-4 to cellular receptors |
| 03/19/2002 | US6358443 Directing microdroplets into freezing section containing a liquefied gas; contacting frozen microdroplets in extraction section with liquid non-solvent to extract solvent into non-solvent to form microparticles |
| 03/19/2002 | CA2099779C Mixed specificity fusion proteins |
| 03/19/2002 | CA1341349C Functionalized polyamine chelants and rhodium complexes thereof for conjugation to antibodies |
| 03/18/2002 | CA2357685A1 Transfer factor composition and process for producing same |
| 03/15/2002 | CA2339327A1 Vaccines and agents for inducing immunity in fish against rickettsial diseases, and associated preventative therapy |
| 03/14/2002 | WO2002021141A2 Methods and compositions for diseases associated with amyloidosis |
| 03/14/2002 | WO2002020830A2 Test systems based on transmembrane receptors from helminths and the use thereof for identifying and characterizing compounds |
| 03/14/2002 | WO2002020822A2 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | WO2002020813A2 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 03/14/2002 | WO2002020809A1 A delivery method for the tumor specific apoptosis inducing activity of apoptin |
| 03/14/2002 | WO2002020769A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | WO2002020762A2 Tnf receptor-like molecules and uses thereof |
| 03/14/2002 | WO2002020736A2 Proteases |
| 03/14/2002 | WO2002020732A2 Regulation of human map kinase phosphatase-like enzyme |
| 03/14/2002 | WO2002020724A2 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | WO2002020723A2 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | WO2002020722A2 Methods and compositions for in vitro targeting |
| 03/14/2002 | WO2002020721A2 Vectors derived from south african arbovirus no. 86 |
| 03/14/2002 | WO2002020718A2 Osteoclast-associated receptor |
| 03/14/2002 | WO2002020622A1 A mixture of non-sulfated fucose-based oligosaccharides, a cosmetic or pharmaceutical composition comprising said mixture and its use in cosmetics or pharmacy |
| 03/14/2002 | WO2002020619A2 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 03/14/2002 | WO2002020617A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 03/14/2002 | WO2002020616A1 Hla-a2.1 binding peptides and their uses |
| 03/14/2002 | WO2002020615A2 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 03/14/2002 | WO2002020571A2 Attenuated hiv strains and use thereof |
| 03/14/2002 | WO2002020569A2 Mammalian genes; related reagents and methods |
| 03/14/2002 | WO2002020565A2 Collections of repeat proteins comprising repeat modules |
| 03/14/2002 | WO2002020560A1 Novel human cancer/testis antigen and gene thereof |
| 03/14/2002 | WO2002020555A2 Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components |
| 03/14/2002 | WO2002020554A2 Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines |
| 03/14/2002 | WO2002020466A1 Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents |
| 03/14/2002 | WO2002020055A1 Remedies for heart failure |
| 03/14/2002 | WO2002020054A2 Methods of treatment and diagnosis of hcv infection in cns based on magnetic resonance spectroscopy |
| 03/14/2002 | WO2002020053A1 Hla binding peptides and their uses |
| 03/14/2002 | WO2002020052A1 Use of lipopeptides for immunotherapy of hiv-positive subjects |
| 03/14/2002 | WO2002020050A2 Eiav p26 deletion vaccine and diagnostic |
| 03/14/2002 | WO2002020049A2 Eiav chimeric vaccine and diagnostic |
| 03/14/2002 | WO2002020048A1 A classical swine fever virus epitope vaccine and its producing method |
| 03/14/2002 | WO2002020047A2 Chlamydial peptides and their mimics in demyelinating disease |
| 03/14/2002 | WO2002020046A1 Multicomponent mscramm vaccine |
| 03/14/2002 | WO2002020045A2 Vaccine against microbial pathogens |
| 03/14/2002 | WO2002020044A1 Superantigen enhancement of specific immune responses |
| 03/14/2002 | WO2002020042A1 A method for inducing immunity comprising phagocytic particles and atp receptors |
| 03/14/2002 | WO2002020041A2 Eia vaccine and diagnostic |
| 03/14/2002 | WO2002020040A1 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same |
| 03/14/2002 | WO2002020039A2 Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites |
| 03/14/2002 | WO2002020038A2 Method for down-regulating ige |
| 03/14/2002 | WO2002020035A1 Hla binding peptides and their uses |
| 03/14/2002 | WO2002020004A1 Methods for inhibiting inflammatory disease |
| 03/14/2002 | WO2002019986A1 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions |
| 03/14/2002 | WO2002019968A2 Genetically engineered co-expression dna vaccines, construction methods and uses thereof |
| 03/14/2002 | WO2002019960A2 Purification, characterization and use of protective antigenic structures against trypanosomes and related parasites |
| 03/14/2002 | WO2001096564A3 Hla-g (hla-g7) isoform and its applications |
| 03/14/2002 | WO2001083713A3 The use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same |
| 03/14/2002 | WO2001081581A3 Compositions and methods for the therapy and diagnosis of acne vulgaris |
| 03/14/2002 | WO2001078655A3 Methods and compositions for heat shock protein mediated immunotherapy of melanoma |
| 03/14/2002 | WO2001077358A3 Herpes viruses for immune modulation |
| 03/14/2002 | WO2001068129A3 Adjuvant for vaccines |
| 03/14/2002 | WO2001066149A3 Nucleic acid formulations for gene delivery and methods of use |
| 03/14/2002 | WO2001066138A3 Dna vaccines against poxviruses |